Does the assessment of troponin and brain natriuretic peptide levels predict cardiotoxicity in cancer patients receiving cancer therapy?
Elevated troponin levels can predict LV dysfunction in cancer patients, suggesting its potential utility as a screening tool to identify patients needing cardio-oncology referral and preventive strategies.
Elevated troponin levels predict LV dysfunction in patients receiving cancer therapy. Assessment of troponin levels may qualify as a screening test to identify patients who require referral to cardio-oncology units and benefit from preventive strategies. Further evidence is required for both biomarkers.
Michel et al. (Tue,) studied this question.